Liver function improver

Abstract

To provide a liver function improver having high liver-function improvement action.SOLUTION: A liver function improver comprises a tectorigenin, and specific other components such as at least one vitamin selected from vitamin B2, sodium pantothenate, biotin, and vitamin E.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a liver function improving agent, and more particularly to a liver function improving agent characterized by containing tectorigenins and other specific components. [Background technology]

[0002] Tectorigenins are flavonoids found in plants of the Iridaceae and Fabaceae families, and are known to activate sirtuins (see Patent Document 1) and activate the expression of the Bmal1 gene (see Patent Document 2). Since tectorigenins are found in plants, they are thought to be relatively safe and easy to ingest on a daily basis, but there are still many unknowns about their activity and functions. [Prior art documents] [Patent documents]

[0003] [Patent Document 1] Japanese Patent Application Laid-Open No. 2006-298876 [Patent Document 2] Japanese Patent Application Laid-Open No. 2013-56866 Summary of the Invention [Problem to be solved by the invention]

[0004] Therefore, in the present invention, various studies were conducted to combine tectorigenins with other specific components in order to obtain an unprecedentedly excellent liver function improving agent. [Means for solving the problem]

[0005] The present inventors have tested the liver function improving effect of combining tectorigenins with a wide variety of ingredients, and have found that the liver function improving effect is dramatically improved by combining tectorigenins with specific other ingredients.

[0006] The present invention specifically relates to The liver function improving agent is characterized by containing tectorigenins and at least one component selected from the group consisting of the following (a) to (f): (a) at least one vitamin selected from vitamin B2, sodium pantothenate, biotin, and vitamin E (b) at least one plant material selected from mugwort, black ginger (Kaempferia parviflora), rice bran, and rice germ; (c) At least one fermentation-related ingredient selected from grain koji, black vinegar, wheat bran fermented extract powder, moromi vinegar, and beer yeast (d) at least one amino acid (including a salt) selected from alanine, isoleucine, lysine, proline, and tyrosine; (e) at least one functional additive selected from iron, molybdenum, zinc, titanium, gallic acid, chlorogenic acid, curcumin, caffeine, L-carnitine, and α-lipoic acid; (f) At least one sweetener selected from aspartame, maltose, and fructooligosaccharides

[0007] Furthermore, the present invention is preferably a liver function improving agent obtained by adding a component consisting of tectorigenins and at least one component selected from the group consisting of (a) to (f).

[0008] Furthermore, the present invention is preferably a liver function improving agent characterized by being in the form of a tablet, capsule, powder, granule, or liquid. [Effects of the Invention]

[0009] According to the present invention, a liver function improving agent having an excellent liver function improving effect can be provided. DETAILED DESCRIPTION OF THE INVENTION

[0010] The liver function improving agent of the present invention is not particularly limited as long as it contains tectorigenins and specific other components. Furthermore, the liver function improving agent of the present invention has an excellent liver function improving effect and is expected to enhance liver function or suppress liver damage. In particular, the combination of tectorigenins of the present invention with specific other components prevents damage to liver cells. This is expected to suppress the escape of aspartate aminotransferase (AST), alanine transaminase (ALT), and γ-glutamyltranspeptidase (γ-GTP) in liver cells into the blood.

[0011] The tectorigenins used in the present invention refer to tectorigenin, its glycosides or derivatives, and mixtures thereof. There are no particular limitations on the tectorigenins as long as they are commonly known tectorigenins, but tectorigenin, tectoridin, and tectorigenin 7-O-xylosylglucoside (TGXG) are preferred, and mixtures thereof are particularly preferred.

[0012] The tectorigenins used in the present invention may be synthesized or may be contained in plants, but from the viewpoint of safety, etc., those extracted from plants are preferred, and those extracted from plants of the Iridaceae or Leguminosae family are particularly preferred. Known examples of plants of the Iridaceae or Leguminosae family include Japanese iris, iris, kudzu, and iris.

[0013] When extracting tectorigenins from plants, any part of the plant, such as the trunk, branches, fruit, leaves, flowers, seeds, bark, sap, roots, stems, or buds, can be used; however, for ease of use, leaves and flowers are preferred. The plants may be used raw, but considering extraction efficiency, it is preferable to perform extraction after processing such as shredding, drying, or crushing. Extraction can be performed by immersing the plants in an extraction solvent, or, to increase extraction efficiency, by stirring or homogenizing in the extraction solvent. The appropriate extraction temperature is from about 5°C to a temperature below the boiling point of the extraction solvent. The extraction time varies depending on the type of extraction solvent and the extraction temperature, but is preferably from about 1 hour to 30 days.

[0014] As the extraction solvent, in addition to water, physiological saline, phosphate buffer, phosphate buffered physiological saline, etc. may be used. Also usable are polar organic solvents such as lower alcohols such as methanol, ethanol, propanol, isopropanol, etc.; polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, glycerin, etc.; ethers such as ethyl ether, propyl ether, etc.; esters such as ethyl acetate, butyl acetate, etc.; ketones such as acetone, ethyl methyl ketone, etc.; and one or more of these may be selected and used. It is possible.

[0015] The tectorigenins contained in the extracts of Iridaceae and Fabaceae using the above solvents can be used as they are, but they may also be used after being concentrated, dried, and then redissolved in water or a polar solvent, or after being subjected to purification treatments such as bleaching, deodorization, and desalting within the scope that does not impair their physiological effects, or after being subjected to fractionation treatments such as column chromatography.

[0016] Tectorigenins used in the present invention can be obtained by extraction from plants as described above, but synthetic products synthesized by methods commonly known to those skilled in the art, commercially available products, and processed products obtained by subjecting commercially available products to chemical treatment, enzyme treatment, purification treatment, etc. For example, tectorigenin and tectoridin can be obtained from Kanto Chemical Co., Ltd.

[0017] The content of tectorigenins is not particularly limited, and is, for example, 0.01% by mass or more, preferably 0.05 to 20% by mass, more preferably 0.1 to 10% by mass, and particularly preferably 0.5 to 5% by mass, relative to the total amount of the liver function improving agent of the present invention. In this case, the content of tectorigenins refers to the total content of tectorigenin, tectoridin, and TGXG.

[0018] [Other ingredients] The liver function improving agent of the present invention is characterized by containing tectorigenins and specific other components. The specific other components are not limited to components that have little or no liver function improving ability, and can be combined with tectorigenins to synergistically improve liver function improving ability. However, it is particularly desirable to contain at least one component selected from the group consisting of (a) to (f) described below.

[0019] (a) Vitamins In the liver function improving agent of the present invention, it is preferable to use at least one vitamin selected from vitamin B2, sodium pantothenate, biotin, and vitamin E as another ingredient together with tectorigenins. These vitamins are not particularly limited, but commercially available vitamins used as ingredients in cosmetics and food and beverages can be used. When combined with tectorigenins, these other ingredients not only provide a synergistic liver function improving effect, but can also improve the taste of tectorigenins. Furthermore, when combined with tectorigenins to form a beverage or tablet, the absorbability of tectorigenins into the body can be increased.

[0020] (b) Plant material In the liver function improving agent of the present invention, it is preferable to use at least one plant material selected from mugwort (Artemisia indica), black ginger (Kaempferia parviflora), rice bran, and rice germ as other ingredients together with tectorigenins. When combined with tectorigenins, these other ingredients not only provide a synergistic liver function improving effect, but also improve the taste of tectorigenins. Furthermore, the resulting product has better color and dispersibility than when tectorigenins alone are dissolved in water.

[0021] Of these plant materials, mugwort and black ginger may be used in any part of the plant, such as flowers, leaves, stems, or roots, but typically edible parts are preferred. The plant material itself (including dried products), its pulverized product, squeezed juice, extract, etc., can be used. Examples of pulverized products include powder and granules. The squeezed juice and extract may be in liquid form, but can also be used as a paste or dry powder. The extract can be obtained by extraction using an appropriate solvent, and examples of the solvent that can be used include water, ethanol, and aqueous ethanol.

[0022] Rice bran is obtained by separating the pericarp, seed coat, germ, etc. that are produced when rice is polished. There are no particular limitations on the rice bran, but commercially available rice bran used as a raw material for cosmetics and food and beverages can be used.

[0023] Rice germ includes the germ of rice and the isolated components contained in the germ. There is no particular limitation on the rice germ, but commercially available rice germs used as ingredients in cosmetics and food and beverages are used. It is possible.

[0024] (c) Fermentation-related materials In the liver function improving agent of the present invention, it is preferable to use at least one fermentation-related material selected from grain koji, black vinegar, wheat bran fermented extract powder, moromi vinegar, and brewer's yeast as other ingredients together with tectorigenins. When these other ingredients are combined with tectorigenins, not only can they achieve a synergistic liver function improving effect, but they can also improve the taste of tectorigenins. Furthermore, they can have better color and dispersibility than when only tectorigenins are dissolved in water.

[0025] These fermentation-related materials are not particularly limited, and may be used as they are, or may be dried and pulverized. Extracts from the fermentation-related materials may also be used, and the extracts may be used as they are or pulverized. Examples of pulverized materials include powders and granules. The extracts may be in liquid form, but can also be used as a paste or dry powder. The extracts can be obtained by extraction using an appropriate solvent, and examples of the solvent that can be used include water, ethanol, and aqueous ethanol.

[0026] Grain koji is made by fermenting seven ingredients - barley, foxtail millet, barnyard millet, common millet, sorghum millet, purple black rice, and rice flour - using koji mold.The black vinegar, wheat bran fermentation extract powder, moromi vinegar, and brewer's yeast are not particularly limited, but commercially available products used as ingredients in cosmetics and food and beverages can be used.

[0027] The koji used for fermenting grain koji, black vinegar, wheat bran fermented extract powder, and moromi vinegar is not particularly limited, but may be any koji obtained by fermenting grains such as rice, barley, soybeans, foxtail millet, barnyard millet, and millet with koji mold. The koji mold used for fermentation may be any of yellow koji mold, blue koji mold, white koji mold, black koji mold, red koji mold, etc. Specific examples include microorganisms belonging to the genus Aspergillus, such as Aspergillus awamori (black koji mold), Aspergillus saitoi (black koji mold), Aspergillus nakazawai (black koji mold), Aspergillus usamii (black koji mold), Aspergillus luchensis (black koji mold), Aspergillus niger (black koji mold), Aspergillus kawachii (white koji mold), and Aspergillus oryzae (yellow koji mold).

[0028] (d) amino acids In the liver function improving agent of the present invention, it is preferable to use at least one amino acid selected from alanine, isoleucine, lysine, proline, and tyrosine as another component together with tectorigenins. Examples of salts include sodium salts and hydrochlorides. These amino acids are not particularly limited, but commercially available amino acids used as ingredients in cosmetics and food and beverages can be used. When combined with tectorigenins, these other components not only achieve a synergistic liver function improving effect, but also improve the taste of tectorigenins. Furthermore, the resulting product has better color and dispersibility than when tectorigenins alone are dissolved in water.

[0029] (e) Functional additives In the liver function improving agent of the present invention, it is preferable to use at least one functional additive selected from iron, molybdenum, zinc, titanium, gallic acid, chlorogenic acid, curcumin, caffeine, L-carnitine, and α-lipoic acid as other components together with tectorigenins. These functional additives are not particularly limited, but commercially available additives used as ingredients in cosmetics and food and beverages can be used. When combined with tectorigenins, these other components not only achieve a synergistic liver function improving effect, but also improve the taste of tectorigenins. Furthermore, the resulting product has better color and dispersibility than when tectorigenins alone are dissolved in water.

[0030] (f) Sweeteners In the liver function improving agent of the present invention, it is preferable to use at least one sweetener selected from aspartame, maltose, and fructooligosaccharides as other ingredients together with tectorigenins. These sweeteners are not particularly limited, but commercially available sweeteners used as ingredients in cosmetics and food and beverages can be used. When combined with tectorigenins, these other ingredients not only achieve a synergistic liver function improving effect, but also improve the taste of tectorigenins. Furthermore, the resulting product has better color and dispersibility than when tectorigenins alone are dissolved in water.

[0031] [Form of use] The liver function improver of the present invention may be any product that can be distinguished from other products in that it is used to improve liver function, and examples thereof include products that display the liver function improving function on the product itself, packaging, instructions, or promotional materials related to the liver function improver of the present invention. Displaying the liver function improving function means, for example, displaying that the product is useful for maintaining and improving liver health, such as for those who want to maintain liver health, maintaining liver health, supporting liver function, for liver health, or improving liver function, or displaying that appeals to subjects who are concerned about liver function, such as those who are concerned about liver function, those who are concerned about liver health, and those who drink a lot of alcohol.

[0032] Specific examples of uses of the liver function improving agent of the present invention include pharmaceuticals (including quasi-drugs), cosmetics, general foods, functional foods, as well as so-called health foods such as foods for specified health uses and functional foods whose efficacy has been approved by the Consumer Affairs Agency.

[0033] The liver function improving agent of the present invention can be used for external or oral administration. There are no particular limitations on the external preparation as long as it is applied to the skin, scalp, etc., and its form can include external preparations for the skin such as ointments, creams, gels, lotions, emulsions, packs, and compresses, as well as injections.

[0034] Furthermore, when the liver function improving agent of the present invention is used as an oral preparation, its form can be, for example, a tablet, capsule, powder, granule, liquid, granule, bar, plate, block, solid, pill, paste, cream, caplet, gel, chewable, or stick. Among these, tablets, capsules, powder, granule, and liquid forms are particularly preferred because they are easy to ingest and can easily achieve liver function improving effects. Specific examples include supplements, food additives, packaged beverages filled in PET bottles, cans, or bottles, and instant powdered (granular) beverages that can be dissolved in water (hot water), milk, fruit juice, or the like. These are preferred because they are easy to consume during meals and can be more palatable.

[0035] The content of tectorigenins and other components in the liver function improving agent of the present invention may be appropriately determined within the range in which the effects are exhibited. The liver function improving agent of the present invention may contain tectorigenins as active ingredients, or may contain tectorigenins and other components as active ingredients.

[0036] Generally, when the liver function improving agent of the present invention is a pharmaceutical or supplement (tablet, capsule), it is preferable that the tectorigenins and other components account for 0.01 to 100% by mass of the total, calculated on a dry mass basis, more preferably 0.1 to 85% by mass, and even more preferably 0.5 to 70% by mass.

[0037] When the liver function improving agent of the present invention is a packaged beverage (liquid), the tectorigenins and other components are preferably contained in an amount of 0.0001 to 10% by mass, more preferably 0.0003 to 6% by mass, and even more preferably 0.0005 to 4% by mass, of the total amount converted to dry mass.

[0038] Furthermore, when the liver function improving agent of the present invention is an instant powdered drink (powder) or an instant granular drink (granules), the tectorigenins and other components are preferably contained in an amount of 0.001 to 50% by mass, and more preferably 0.01 to 40% by mass, calculated as a dry mass. It is more preferable that the content of the inorganic filler is 0.1 to 30 mass %.

[0039] To more effectively exert the effects of the present invention, the tectorigenins and other components preferably account for 80% by mass or more of the total liver function improver of the present invention (excluding water) in terms of dry mass, more preferably 90% by mass or more, even more preferably 95% by mass or more, and particularly preferably 100% by mass. Furthermore, when the liver function improver of the present invention contains any of components (a) to (f), the components contained therein are preferably composed only of the other components described in the present invention. That is, when the liver function improver of the present invention contains, for example, component (a) plant material, it is preferable that it be composed so as not to contain any other plant material for beverages.

[0040] The intake amount of the liver function improving agent of the present invention is not particularly limited, but from the viewpoint of more significantly exhibiting the effects of the present invention, it is preferable that the daily intake amount of tectorigenins and other components is 5 mg / day or more, more preferably 10 mg / day or more, and even more preferably 20 mg / day or more. The upper limit is not particularly limited, but is, for example, 2 g / day, preferably 1 g / day. The liver function improving agent of the present invention can be stored as a daily amount in one container or divided into, for example, 2 to 3 multiple containers so that the daily intake amount is the above-mentioned intake amount.

[0041] The blending mass ratio of tectorigenins to other components is preferably in the range of 0.0001:1 to 60:1, more preferably in the range of 0.0005:1 to 50:1, even more preferably in the range of 0.001:1 to 40:1, and particularly preferably in the range of 0.003:1 to 30:1, when calculated as dry mass. When the blending ratio of tectorigenins to other components is in the above range, the effects of the present invention can be more effectively exhibited.

[0042] The liver function improving agent of the present invention can be produced by a known formulation method by adding, as necessary, orally acceptable additives and components other than tectorigenins and other components.

[0043] Furthermore, the liver function improving agent of the present invention can include foods for improving liver function containing tectorigenins and other components, as well as foods for improving liver function obtained by adding tectorigenins and other components to foods, and can include, for example, foods in which the content of the tectorigenins and other components of the present invention is increased compared to normal foods (including natural foods), and foods in which tectorigenins and other components of the present invention are added to foods that do not normally contain the tectorigenins and other components of the present invention. The addition of tectorigenins and other components can be done by adding each component separately or simultaneously, or by adding them together with other components other than tectorigenins and other components. It may be added.

[0044] One of the uses of the liver function improving agent of the present invention is to add it to food, and examples of foods include beverages such as carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, smoothies, and green juice; frozen desserts such as ice cream, ice sherbet, and shaved ice; noodles such as soba, udon, harusame, Chinese noodles, and instant noodles; sweets such as candy, candy, gum, chocolate, tablet sweets, snacks, biscuits, jelly, jam, cream, baked goods, and bread; and seafood and livestock products such as kamaboko, ham, and sausage. processed foods; dairy products such as processed milk, fermented milk, and yogurt; oils and fats such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, and dressing, and processed foods thereof; seasonings such as sauces and soy sauce; and retort pouch foods such as curry, stew, oyakodon, porridge, rice porridge, Chinese rice bowl, katsudon, tempura bowl, beef bowl, hayashi rice, omelet rice, oden, mapo dolphin, gyoza, shumai, hamburger steak, meatballs, various sauces, and various soups. [Example]

[0045] The present invention will be described below based on examples.

[0046] [Test example] The tectorigenins used were a mixture of tectorigenin, tectoridin, and TGXG extracted from plants (tectorigenin:tectoridin:TGXG=5.4:34.1:60.5).

[0047] [Liver function improvement confirmation test] (Preparation of sample solution) Human hepatoma-derived cells (HepG2) were cultured in 10% FBS-DMEM (hereafter referred to as DMEM), and then 4.0 × 10 cells were added to each well of a 96-well plate. 4 The cells were seeded at a density of 100 cells / well and pre-cultured for 24 hours in a 5% CO2 incubator at 37°C. 200 μL of sample solutions prepared using DMEM to the predetermined concentrations shown in Tables 1 to 6 below were added to the cells, and the cells were cultured in a 5% CO 2 incubator for 24 hours. When vitamin E, black ginger, curcumin, or α-lipoic acid was added as other components in the preparation of the sample solution, each test substance was dissolved in DMSO and adjusted so that the final DMSO concentration was 0.25%.

[0048] (Measurement method) The medium was removed from the sample solution, and 150 μL of Cell Counting Kit-8 solution diluted 30-fold with DMEM was added. The sample was placed in a 37°C, 5% CO2 incubator to allow for adequate color development, and then the absorbance at 450 nm was measured. As controls, DMEM containing 0.25% DMSO was used for the test substances dissolved in DMSO, and DMEM was used for the other test substances.

[0049] The hepatocyte activation rate of each test substance was calculated using the following formula. Hepatocyte activation rate (%) % of control = (Data sample-Data blank) / (Data control-Data blank)×100 (Wherein, Data sample: Fluorescence intensity of test solution (test) Data control: Fluorescence intensity of control (test) Data blank: Fluorescence intensity of test solution (blank)

[0050] The results are shown in Tables 1 to 6. The values ​​other than the hepatocyte activation rate for each test group indicate the final concentration of tectorigenins or other components, and all units are μg / mL. The hepatocyte activation rate for each test group indicates the change in value relative to the hepatocyte activation rate of the control.

[0051] In addition, other ingredients that increased the hepatocyte activation rate (change value) by 10 points or more when used in combination with tectorigenins compared to the sum of the hepatocyte activation rate (change value) when tectorigenins were used alone and the hepatocyte activation rate (change value) when the other ingredient was used alone were considered to have a synergistic effect with tectorigenins, and this is shown in Tables 1 to 6.

[0052] [Table 1]

[0053] All other components listed in Table 1 were commercially available.

[0054] [Table 2]

[0055] In Table 2, commercially available crushed mugwort powder was used for mugwort, and commercially available 60% ethanol extract of black ginger rhizome was used for black ginger. All other ingredients except for mugwort and black ginger were commercially available.

[0056] [Table 3]

[0057] All other components listed in Table 3 were commercially available.

[0058] [Table 4]

[0059] All other components listed in Table 4 were commercially available.

[0060] [Table 5]

[0061] All other components listed in Table 5 were commercially available. Iron was made from iron chloride, molybdenum from molybdenum chloride, titanium from titanium dioxide, and zinc from zinc gluconate.

[0062] [Table 6]

[0063] All other components listed in Table 6 were commercially available.

[0064] As shown in Tables 1 to 6, the hepatocyte activation rate was synergistically increased by combining tectorigenins with other specific components of the present invention. Therefore, the liver function improving agent of the present invention can be used for the purpose of increasing hepatic blood flow, promoting bile secretion, promoting liver tissue respiration, or suppressing viral, drug-induced, or alcoholic liver damage.

[0065] (Comparative Example) Using the same method as in the examples, tests were conducted to confirm the liver function improvement of the following other ingredients.When the vitamins vitamin A (tectorigenin), barley leaf powder which is a plant material, vegetable fermentation products which are fermentation-related materials, arginine which is an amino acid, calcium which is a functional additive, and trehalose which is a sweetener were used, the liver cell activation rate (change value) when used in combination with any of the tectorigenins was not increased by 10 points or more compared to the sum of the liver cell activation rate (change value) when using the tectorigenins alone and the liver cell activation rate (change value) when using the other ingredients alone, and no synergistic effect on liver cell activation was confirmed.

[0066] (Example 1: Lotion) The liver function improving agent of the present invention was prepared in the form of a lotion by mixing 0.01 parts by mass of tectorigenins, 0.01 parts by mass of vitamin B2, 10 parts by mass of glycerin, 3 parts by mass of diglycerin, 12 parts by mass of 1,3-butylene glycol, 3 parts by mass of pentylene glycol, 0.1 parts by mass of sodium hyaluronate, 0.01 parts by mass of citric acid, 0.02 parts by mass of sodium citrate, 0.1 parts by mass of xanthan gum, 0.15 parts by mass of methylparaben, 0.2 parts by mass of carbomer, 0.03 parts by mass of sodium hydroxide, and the remainder being water, making the total 100 parts by mass.

[0067] (Example 2: Shampoo) Taking the total as 100 parts by mass, 0.01 parts by mass of tectorigenins, 0.02 parts by mass of mugwort leaf extract, 7.5 parts by mass of sodium laureth sulfate, 4.2 parts by mass of cocamidopropyl betaine, 3 parts by mass of cocamide DEA, 0.1 parts by mass of 1,3-butylene glycol, 0.225 parts by mass of polyquaternium-10, 0.15 parts by mass of citric acid, 0.05 parts by mass of sodium citrate, 0.9 parts by mass of phenoxyethanol, and the remainder, water, were mixed to prepare a liver function improving agent of the present invention in the form of a shampoo.

[0068] (Example 3: Soap) The liver function improving agent of the present invention was prepared in the form of soap by mixing and solidifying 0.5 parts by mass of tectorigenins, 0.5 parts by mass of black vinegar, 2 parts by mass of glycerin, 1 part by mass of olive oil, 0.1 parts by mass of EDTA-tetrasodium, 0.2 parts by mass of tetrasodium etidronate, and the remainder of the soap base, with the total amount being 100 parts by mass.

[0069] (Formulation example 4: Emulsion) The liver function improving agent of the present invention was prepared in the form of an emulsion by mixing 0.1 parts by mass of tectorigenins, 0.1 parts by mass of tyrosine, 3 parts by mass of sucrose fatty acid ester, 12 parts by mass of glycerin, 6 parts by mass of squalane, 24 parts by mass of dimethyl silicone oil, 1 part by mass of polypropylene glycol, 0.06 parts by mass of thickener, 0.2 parts by mass of phenoxyethanol, 5 parts by mass of ethanol, 0.01 parts by mass of sodium hydroxide, and the remainder being purified water, making the total 100 parts by mass.

[0070] (Example 5: Cosmetic cream) Based on a total of 100 parts by mass, the ingredients are: 0.1 parts by mass of tectorigenins, 0.1 parts by mass of chlorogenic acid, 15.0 parts by mass of squalane, 4.0 parts by mass of octyldodecyl myristate, 0.2 parts by mass of hydrogenated soybean phospholipid, 2.4 parts by mass of butyl alcohol, 1.5 parts by mass of hydrogenated oil, 1.5 parts by mass of stearic acid, 1.5 parts by mass of lipophilic glycerin monostearate, 0.5 parts by mass of polyglyceryl monostearate, 0.8 parts by mass of behenyl alcohol, 0.7 parts by mass of polyglyceryl monomyristate, 0.3 parts by mass of white beeswax, 0.1 parts by mass of d-δ-tocopherol, 0.3 parts by mass of methylparaben, C10-3 A liver function improving agent of the present invention was prepared in the form of a cosmetic cream by mixing 0.2 parts by mass of alkyl-modified carboxyvinyl polymer, 0.1 parts by mass of carboxyvinyl polymer, 18.0 parts by mass of 1,3-butanediol, 0.1 parts by mass of sodium hydroxide, and the remainder being purified water.

[0071] (Example 6: Pack) The liver function improving agent of the present invention was prepared in the form of a pack by mixing 0.1 parts by mass of tectorigenin extract, 0.01 parts by mass of aspartame, 20.0 parts by mass of polyvinyl alcohol, 5.0 parts by mass of glycerin, 20.0 parts by mass of ethanol, 6.0 parts by mass of kaolin, 0.2 parts by mass of preservative, 0.1 parts by mass of fragrance, and the remainder being purified water, making the total 100 parts by mass.

[0072] (Composition Example 7: Tablets) The liver function improving agent of the present invention was prepared in tablet form by mixing and compressing 5 parts by mass of tectorigenin powder, 8 parts by mass of sodium pantothenate, 5 parts by mass of vitamin B1, 20 parts by mass of crystalline cellulose, 50 parts by mass of lactose, 4 parts by mass of magnesium stearate, and the remainder of cornstarch, totaling 100 parts by mass.

[0073] (Formulation Example 8: Granules) The liver function improving agent of the present invention was prepared in the form of granules by mixing and granulating 5 parts by mass of tectorigenin powder, 15 parts by mass of black ginger extract, 10 parts by mass of lactose, 1 part by mass of calcium stearate, and the remainder of crystalline cellulose, with the total amount being 100 parts by mass.

[0074] (Formulation Example 9: Capsules) The liver function improving agent of the present invention was prepared in the form of a capsule by mixing 2.5 parts by mass of tectorigenin extract, 20 parts by mass of grain koji, 8 parts by mass of lecithin, and the remainder of olive oil, with the total amount being 100 parts by mass, and encapsulating this mixture in a capsule shell to form the liquid content.

[0075] (Example 10: Liquid) The liver function improving agent of the present invention was prepared in the form of a liquid by mixing 0.33 parts by mass of tectorigenin powder, 0.1 parts by mass of L-alanine, 10 parts by mass of high fructose glucose liquid sugar, 1 part by mass of citric acid, 0.02 parts by mass of sodium benzoate, 2 parts by mass of flavoring, 0.05 parts by mass of sucralose, 0.03 parts by mass of acesulfame potassium, and the remainder, making a total of 100 parts by mass.

Claims

[Claim 1] An oral composition (excluding those containing coffee) characterized by comprising at least one selected from tectorigenin, tectoridin, and tectorigenin 7-O-xylosylglucoside, and at least one selected from chlorogenic acid (excluding that derived from coffee) and caffeine (excluding that derived from coffee).

Images